---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021953"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:50:15.269702+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Larimar Phase 2 trial shows frataxin increases in skin and buccal cells; Q1 net loss $6.5M

## Summary
- Median placebo-adjusted frataxin increase from baseline: 3.5 pg/µg in skin, 0.9 pg/µg in buccal cells at day 14.
- CTI-1601 generally well tolerated; one severe allergic reaction led to withdrawal; 8 of 9 completed the cohort.
- Data submitted to FDA; meeting scheduled Q2 2023; program update expected Q3 2023.
- Q1 2023 net loss $6.5M ($0.15/diluted share) vs $8.9M ($0.49) in Q1 2022; cash $111.5M as of March 31, 2023.

## SEC filing metadata
- accession: 0000950170-23-021953
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/0000950170-23-021953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/lrmr-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021953
- JSON: https://secwatch.observer/filing/0000950170-23-021953.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021953.txt

## Key facts
- Earnings Releases
  Larimar Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 15, 2023, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/0000950170-23-021953-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.